Sravan K Jonnalagadda
Affiliations: | University of Minnesota Duluth, Duluth, MN, United States |
Area:
Chemistry, Medicinal chemistryGoogle:
"Sravan Jonnalagadda"Bio:
M.S: https://hdl.handle.net/11299/170739
Ph.D: https://hdl.handle.net/11299/224530
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Venkatram Mereddy | grad student | 2013-2019 | University of Minnesota Duluth | |
| (M.S: 'Synthesis of functionalized benzoxaboroles' (2014); Ph.D: 'Novel Heterocyclic Compounds as Tumor Metabolism Inhibitors') | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Maddeboina K, Jonnalagadda SK, Morsy A, et al. (2023) Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model. Journal of Medicinal Chemistry |
| Huwaimel BI, Jonnalagadda SK, Jonnalagadda S, et al. (2023) Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold. Drug Development Research |
| Huwaimel BI, Jonnalagadda S, Jonnalagadda S, et al. (2022) Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation. Bioorganic & Medicinal Chemistry. 67: 116805 |
| Jonnalagadda SK, Huwaimel BI, Jonnalagadda S, et al. (2022) Access to Highly Strained Tricyclic Ketals Derived from Coumarins. The Journal of Organic Chemistry. 87: 4476-4482 |
| Nelson GL, Ronayne CT, Solano LN, et al. (2021) Synthesis and biological evaluation of N, N-dialkylcarboxy coumarin-NO donor conjugates as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters. 128411 |
| Penning TM, Jonnalagadda S, Trippier PC, et al. (2021) Aldo-Keto Reductases and Cancer Drug Resistance. Pharmacological Reviews. 73: 1150-1171 |
| Ronayne CT, Jonnalagadda SK, Jonnalagadda S, et al. (2021) Synthesis and biological evaluation of a novel anticancer agent CBISC that induces DNA damage response and diminishes levels of mutant-p53. Biochemical and Biophysical Research Communications. 562: 127-132 |
| Solano LN, Nelson GL, Ronayne CT, et al. (2020) Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents. Scientific Reports. 10: 17969 |
| Jonnalagadda SK, Wielenberg K, Ronayne CT, et al. (2020) Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents. Bioorganic & Medicinal Chemistry Letters. 30: 127259 |
| Sadeghzadeh M, Wenzel B, Gündel D, et al. (2020) Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging. Molecules (Basel, Switzerland). 25 |